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36 N. Saber et al.Results: There was a statistically signiﬁcant reduction in plantar fascia thickness after treatment in
both groups, while no statistically signiﬁcant difference between the study groups. According to
assessment with Mayo clinic scoring system, despite the fact that both groups showed statistically
signiﬁcant improvement at the end of follow up period, there was no statistically signiﬁcant differ-
ence between the study groups.
Conclusion: Both treatment groups showed signiﬁcant clinical and radiological improvement of
plantar fasciitis after therapy with statistically non-signiﬁcant superior results of the extracorporeal
shock wave therapy group. However, we do recommend local steroid injection as our preferred
method of treatment as it attains clinical improvement at a much better cost effective value.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Plantar fasciitis (PF) is the most commonly reported cause of
chronic pain beneath the heel.1,2 About 10% of the population
complains of heel pain at some point in life , and the condition
accounts for about 2.5 million people each year in the United
States.3 The condition is associated with signiﬁcant morbidity
placing activity limitations on the affected patients.4–6
PF is characterized by microscopic tearing of the plantar
fascia, which is a long ligament on the bottom of the foot. This
ligament (the plantar fascia) is responsible for maintaining the
arch of the foot. When the plantar fascia pulls away from the
bone, the heel becomes painful. As a result of continuous
pulling, tissue may react by ﬁlling this space with new bone –
a heel spur. Most people think that heel spurs are the cause
of their foot pain, but the pain is actually caused by the inﬂam-
mation or irritation of the plantar fascia and muscle.5
PF is characterised by pain at the calcaneal origin of the
plantar fascia that is usually worse with their ﬁrst steps in
the morning or after a period of inactivity, and made worse
by increased duration of weight-bearing.1,2 The most common
pathological features are deterioration of collagen ﬁbres, in-
creased secretion of ground substance proteins, focal areas of
ﬁbroblast proliferation and vascular congestion.6
The diagnosis of plantar fasciitis can be made with reason-
able certainty on the basis of clinical assessment alone.4
Ultrasonography has been well recognized as an effective
imaging diagnostic tool for plantar fasciitis,7,8 with advantages
of being non-invasive, well tolerated by patients, cost effective,
free of radiation, and able to provide perfect spatial resolution
for superﬁcial structures.9,10 Given the thickening of the plan-
tar fascia as a commonly observed ﬁnding with ultrasound in
patients with PF, it is postulated that there should be a de-
crease in the plantar fascia thickness as the patients improve
in their symptoms with treatment.11
The goals of treatment are to alleviate pain and restore
function. Treatment of plantar fasciitis is mainly conservative,
with more than 80–90% of patients responding positively.12
Surgical treatment with either open or an endoscopic release
of the plantar fascia has been recommended in patients who
failed to respond to conservative treatment.13,14
Conservative treatment modalities for the treatment of
plantar fasciitis includes, among others: non-steroidal anti-
inﬂammatory drugs, heel cushions, stretch exercise,
physiotherapy, local injections, and extracorporeal shock wave
therapy.14,15 The response of plantar fasciitis to any treatment
is unpredictable.14,16Local injection is a commonly used treatment modality for
PF. Most authors recommend steroid injection,16–19 although
there are some trials for other injectables like botulinum tox-
in,20 hyperosmolar dextrose/lidocaine21 and autologous plate-
let concentrate.22,23
Corticosteroids have been shown to inhibit ﬁbroblast pro-
liferation and expression of ground substance proteins. It is
possible that these known effects may be of beneﬁt in the treat-
ment of plantar fasciitis, as increased ﬁbroblast proliferation
and excessive secretion of proteoglycans are commonly
reported features of the condition.16,24
Shock waves (SWs), deﬁned as a sequence of single sonic
pulses characterised by high peak pressure, a fast rise in pres-
sure and a short lifecycle, are conveyed by an appropriate gen-
erator to a speciﬁc target area. Extracorporeal SW therapy was
ﬁrst used on patients in 1980 to break up kidney stones. This
technique has been successfully employed in orthopaedic dis-
eases such as pseudoarthosis, tendinitis, calciﬁcation of the
shoulder, epicondylitis, plantar fasciitis and several inﬂamma-
tory tendon diseases. In particular, treatment of the tendon
and muscle tissues was found to induce a long-time tissue
regeneration effect in addition to having a more immediate
analgesic and anti-inﬂammatory outcome.25–27
The FDA approved extracorporeal shockwave therapy
(ESWT) for the treatment for plantar fasciitis was in 2000. Since
that time, numerous studies have investigated the use of shock
wave treatments for recalcitrant cases of plantar fasciitis.24
The ESWT are sound waves that create vibrations and
cause controlled injury to the plantar fascia and the
surrounding structures at the heel. The body responds by
increasing its healing ability at that area, stimulating a repair
process. The mechanism of this type of therapy is unknown,
however, it has been suggested that ESWT induce micro-
destruction of avascular or minimally vascular tissues, which
encourage revascularization, the release of local growth factors
and the recruitment of appropriate stem cells ;leading to an
enhancement of the intrinsic wound healing process.5,19,28,33
Several previous studies evaluate the effects of either local
injection therapy or shock wave therapy versus sham therapy
in plantar fasciitis treatment,5,26,30,32 but comparison between
the therapeutic effects of local steroid injection therapy versus
ESWT in PF treatment is lacking in the literature.
The aim of this study was to evaluate and compare the ther-
apeutic effectiveness of ultrasound guided local steroid injec-
tion versus ESWT in plantar fascia thickness through both
clinical and radiological assessment. And to investigate
whether the body mass index (BMI) is a risk factor in each
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injection was related to the accuracy of application and supe-
rior results among available literatures.2. Patients and methods
Between May 2009 and May 2010, 60 patients (27 males, 33
females), otherwise healthy individuals with the diagnosis of
unilateral plantar fasciitis were selected from the out-patient
clinic of orthopaedic and Physical therapy Departments of
Ain Shams University. The diagnosis of PF was made upon
the ﬁnding of tenderness to pressure at the origin of the plantar
fascia on the medial tubercle of the calcaneus, as well as com-
plaint of sharp shooting inferior foot pain, made worse with
activity and/or upon arising in the morning.
Inclusion criteria were: (1) symptomatic heel pain of greater
than 6 months duration and (2) unsuccessful response to
conservative treatment with NSAIDS and stretch exercises.
Patients with systemic inﬂammatory disease, connective tissue
disease, herniated intervertebral disc of the lumbar spine, or
previous local trauma and those with bilateral plantar fasciitis
were excluded from the study. Patients with overt tarsal tunnel
syndrome and those who gave history of recent administration
of local steroid injection within last 3 months were excluded
from the study.2.1. Study design
All patients underwent functional assessment of pain and its
impact on functional status, footwear requirement and effect
on the gait by The Mayo clinical scoring system (total 100
points) which comprises six parameters; (degree of Pain,
activity limitations, footwear or orthotic requirement,
plantar heel tenderness, neuropathy, and antalgic gait).35
Scoring is classiﬁed as excellent results (90–100 points), good
results (80–89), fair (70–79), poor < 70. Weight and height
measurements were recorded to calculate body mass index
(BMI).2.2. Radiographic evaluation
All patients were evaluated by plain heel radiographs to diag-
nose a calcaneal spur or any pre-existing foot anomaly.2.2.1. Ultrasound protocol
All patients were evaluated through high resolution Ultra-
sound imaging, to measure the thickness of plantar fascia in
the affected and the sound sides. The thickness of the plantar
fascia was measured at the thickest portion from the base of
the medial calcaneal tubercle where a bright echogenic line
was easily visible.Figure 1 US localization of the trigger point.2.2.2. Patient consent
All the selected patients were motivated to the treatment, and
they agreed to co-operate and follow the recommendations
and instructions of the clinician.
Patients were randomly assigned to two equal treatment
groups:Group A: Treated with palpation guided injection for two
sessions with 2 weeks interval.
Group B: Treated with medium energy density (0.28 mJ/
mm2); shock wave therapy in the area of maximal
tenderness and positive ﬁnding by U/S for two
sessions with 2 weeks interval.
Local injection for group A was done through aseptic tech-
nique, including twice injection of 2 mL of 4 mg/mL (betameth-
asone diproprionate and betamethasone sodium phosphate),
combined with local anaesthetic; 0.5% zylocaine hydrochlo-
ride). Injection procedures were separated by 2 weeks.
The patient is placed in the lateral recumbent position with
the affected side down. The soft tissue just distal to the calca-
neus is palpated, locating the point of maximal tenderness or
swelling. At the deﬁned soft tissue area, conﬁrmed by ultra-
sound, the needle is inserted through the medial heel, perpen-
dicular to the skin and to the long axis of the ultrasound
transducer (Figs. 1–3). The needle will be advanced under con-
tinuous guidance into the proximal plantar fascia, past the
midline of the width of the foot. Injection into the fat pad at
the base of the foot was totally avoided.
2.3. Shock wave therapy for group B
The patient was lying in prone position over the treating table,
the foot was positioned over pillow to be sure that the foot po-
sition remains constant throughout therapy. All the proce-
dures were performed under local transcutaneous ultrasound
mediated inﬁltration of lidocaine hydrochloride gel 2% and
was explained to the subject prior to the test. Shockwaves were
applied using an electro hydraulic shock wave generator. They
were bundled into a focal area guided by LASER locating aid
which helps to adjust the focal point for the treatment. The
head of the shock wave device was coupled to the most tender
point of proximal heel using ultrasonic gel as a coupling med-
ium, and then two series of shocks were applied. The energy
intensity applied ranged from 14 to 17 kV, 2 Hz, 1000–1500
pulses and were divided into two distinct directional applica-
Figure 4 Machine application to the heel.
Figure 3 Ultrasound guided injection.
Figure 2 Measurement of plantar fascia thickness.
Table 1 Demographic data of the two treatment groups.
Group A (U/S
guidedlocal
injection)
Group B
(ESWT)
t P value
Age (years) 34.2333 ± 6.6731 34.2667 ± 7.1916 .019 0.985
Sex (M/F) 14/16 13/17
BMI 28.8000 ± 2.6182 29.2333 ± 2.8969 .608 0.546
38 N. Saber et al.tions, which were applied at 45 to the target area (Fig. 4).
Same technique is repeated after two weeks.
Following treatment, participants will be advised to avoid
all running and other high impact activities for at least
2 weeks. Patients were followed-up for a mean of 20 weeks
(range 12–24 weeks). At twelve weeks visit, Mayo clinical
scoring is recalculated and thickness of plantar fascia is
re-examined with ultrasound imaging.
2.4. Statistical analysis
The data was collected and tabulated. Statistics was done using
SPSS programme V10. The following tests were done:
– Mean and standard deviation were calculated for numerical
variables.
– Paired sample Student’s t-test was done to compare between
two numerical variables (pre and post).
– Independent sample Student’s t-test was done to compare
between two groups regarding numerical variables.
– Pearson correlation coefﬁcient was done to test linear rela-
tion between two numerical variables.
– P value was calculated for all tests and interpreted as fol-
lowing: <0.05, signiﬁcant; <0.001, highly signiﬁcant;
>0.05, non-signiﬁcant.
3. Results
The demographic data of the patients are listed in (Table 1).
There was no signiﬁcant difference in age, sex, or body mass
index between the two treatment groups.
Twenty patients had calcaneal spurs in their heel on X-ray
ﬁlms. All of the spurs discovered incidentally on X-ray.
At 12 weeks follow up, subjective assessment with Mayo
clinic scoring system and objective assessment through mea-
suring the thickness of planter fascia. The recorded data are
analysed and statistical analysis was conducted with preopera-
tive values.
Objective analysis through measurement of the thickness of
plantar fascia in the ultrasound guided injection group (group
A) showed statistically signiﬁcant improvement from a mean
of 5.9567 ± 0.4591 before treatment to a mean of 3.5433±
.3148 after treatment (t= 39.33, P< 0.00) (Table 2).
Table 2 showed signiﬁcant decrease in PF thickness post
treatment as well as signiﬁcant increase in Mayo CSS post
treatment in group A.
The group of ESWT (group B) had also showed signiﬁcant
decrease in plantar fascia thickness from 5.9367 ± .5353 be-Table 2 Comparison between PF thickness pre and post
treatment in group A. Comparison between Mayo CSS pre and
post treatment in group A.
Before treatment Post treatment t P
PF thickness
5.9567 ± 0.4591 3.5433 ± 0.3148 39.33, <0.001
Mayo CSS
46.66 ± 10.44 84.00 ± 6.6176 23.549 <0.001
Group A
0
1
2
3
4
5
6
7
PF Pre PF Post
Figure 5A Comparison between PF thickness pre and post
treatment in Group A.
Figure 6A PF thickness pre treatment for pt No. 9.
Figure 6B PF thickness post treatment for pt No. 9.
Group B
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Figure 5B Comparison between P thickness pre and post
treatment in Group B.
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(t= 35.7, P< 0.001) (Figs. 5(A and B) and 6(A and B)).
Subjective analysis according to Mayo clinic scoring system,
patients within ultrasound guided injection group (group A)
showed statistically highly signiﬁcant improvement from a
mean of 46.66 ± 10.44 pre injection to a mean of 84.00 ±
6.6176 post injection (t= 23.549, P< 0.001)with 8 (13%)
patients had excellent score. Table 2. The ESWT group (group
B) had also showed highly signiﬁcant improvement from
46.8333 ± 9.60 pre ESWT to a mean of 85.83 ± 6.83 post
ESWT (t= 24.984, P< .001), with 17 (28%) patients had
excellent score.
On comparing the change in Plantar fascia thickness be-
tween group A & B pre treatment and post treatment it showed
non-statistically signiﬁcant difference between 2 groups (t=
0.155, P= 0.877 and t= 1.78, P = 0.079, respectively).
Moreover, there was no statistically signiﬁcant difference in
Mayo CSS score between the two treatment groups before and
after treatment (t= 0.064, P= 0.949 and t= 1.056, P =
0.296, respectively) (Table 2).
Groups A and B were further analysed by way of the
Pearson correlation analysis to reveal a signiﬁcant positive cor-
relation between the plantar fascia thickness before treatment
and BMI (rA= .420, PA< .05 and rB = 0.392, PB < 0.05,
respectively) (Fig. 7A and B), and a signiﬁcant negative corre-
lation between plantar fascia thickness before treatment andthe Mayo CSS pre treatment (rA= 0.681, rB = 0671, respec-
tively, and PA= 0.001, PB = 0.001, respectively).
At a mean follow-up of 4.3 months (range 3–6 months),
90% of patients in both treatment groups showed good to
excellent results according to Mayo clinic scoring system.
Two patients in each group (7%) showed poor response to
treatment.
A total of six patients (20%) showed recurrent symptoms of
plantar fasciitis. The time before recurrence ranged from
5 months to 7 months (mean 6.1 months). The recurrent pa-
tients included three patients from each treatment group.
There were no haematoma, bruising or swelling over the trea-
ted area in both groups.4. Discussion
Although the most common cause of heel pain is plantar fas-
ciitis, the aetiology and treatment are still not fully under-
stood.14,36,37 The diagnosis of plantar fasciitis is based on the
patient’s history and physical ﬁndings for at least 6 months.4
This is in accordance with most studies which included only
patients who had symptoms for 6 months or longer, and
who had failed conservative treatment.35 The population
shared in this study comprised of 35 females (58%) and 25
males (42%) with average age 34.23 ± 6.67 and BMI
Figure 7 Correlation between the plantar fascia thickness before
treatment and BMI in group A and group B.
40 N. Saber et al.28.8000 ± 2.61 randomly divided into two equal groups with
no statistically signiﬁcant difference between them.
The accuracy of radiological studies in diagnosing plantar
heel pain is unknown. In the current study, measurement of
PF thickness by high resolution US technique was chosen based
on conﬁrmed published data that (US) has been well recognized
as an effective imaging diagnostic tool for PF, and able to
provide perfect spatial resolution for superﬁcial structures
and correlated with Patient Self Reported Improvement.8,13,39
Moreover, Ultrasound is superior to MRI for diagnosis of
plantar ﬁbroma as small low signal lesions on MRI are similar
to the normal plantar fascia signal. Ultrasound demonstrates
low echogenicity compared with the echogenic plantar fascia.8
Thickening of the plantar fascia insertion more than 4 mm
would be abnormal and more than 5 mm is suggestive of plan-
tar fasciopathy. This was conﬁrmed by Hammer et al. and
Karabay et al.13,39 In the current study, mean PF thickness of
group A pre-treatment is 5.9567 ± 0.4591 and 5.9367 ±.5353 for group B. As the efﬁcacy of intralesional steroid injec-
tion has been proven in multiple literatures.41,42 In current
study, group A, the US guided local steroid injection technique
was performed and preferred on palpation guided local injec-
tion, to ensure accuracy of application and the objective evalu-
ation of prognosis .This was previously conﬁrmed in the
literature, by many authors43 who did document in their study
that ultrasound guided injection is superior to palpation guided
technique in both the reduction of thickness and recurrence rate
of plantar fasciitis. However, others considered there were no
statistically signiﬁcant differences in the plantar fascia thick-
ness and visual analogue scale of pain among groups treated
by those two techniques. Accordingly, some authors recom-
mended both techniques as more efﬁcacious and cost effective
than other modalities including ESWT.44 Selection of a partic-
ular CS agent for local injection varies across disciplines, with
limited evidence available to assist in decision-making.45,46 In
relation to treatment outcomes, systematic reviews of random-
ised trial data have revealed no difference in clinical efﬁcacy
between various CS types. Additionally, high solubility prepa-
rations (e.g. Betamethasone sodium phosphate) are thought to
reduce the risk of post-injection ﬂare and soft-tissue atrophy.31
Accordingly, Betamethasone sodium phosphate was consid-
ered themost appropriate corticosteroid for use in this trial. This
is comparable toAndrew et al. and Tsai et al.,34,47 they use Beta-
methasone and lidocaine in their design ,they reported that the
thickness had decreased signiﬁcantly 3 months after injection.
In current study, 3 months later, Reassessment by
Ultrasound imaging and subjective assessment by Mayo CSS
was performed for both groups. Group A, showed signiﬁcant
improvement in the subjective (Mayo CSS) and in the objective
(Plantar fascia thickness) assessment methods. This is in accor-
dance to Tsai et al. and Yucel et al.,34,48 they mentioned signif-
icant improvements in plantar fascia thickness, fat pad
thickness, and VAS without signiﬁcant deterioration of the
mechanical properties of the heel pads, in all patients receiving
US guided local steroid injection.
Extracorporeal shockwave therapy (ESWT) for the treat-
ment of musculoskeletal (MSK) disorders evolved in Europe
in the early 1990s.24,29,30 The efﬁcacy of ESWT may be based
on an enhancement of the wound healing cascade; a conver-
sion of a chronic wound to an acute wound ;which can then
go a normal physiological wound healing process.42 Further-
more, clinical observations indicate an immediate increase in
blood ﬂow around the treated area. Nevertheless, the biochem-
ical mechanisms comprise neovascularization at the tendon
junction by inducing of early release of angiogenesis-mediated
growth and proliferating factor.33,35,42
Based on these data, ESWT is applied in two sessions under
local transcutaneous ultrasound mediated inﬁltration of local
anaesthetic to group B as a comparative non-invasive treat-
ment to local steroid injection. Therapy is of an energy density
0.28 mJ/mm2, 2 Hz, 1000–1500 pulses for two sessions. This is
quiet similar to ESWT parameters used by Wen et al.,35 their
patients received 1000 impulses at 16 kV, medium-energy
(0.55 mJ/mm2) in a single session. In current study, plantar fas-
cia thickness reduction was statistically signiﬁcant from
(5.93 ± 0.53) pre ESWT to a mean of (3.37 ± 0.41), 12 weeks
post ESWT. This is in agreement with Khan et al., Speed and
Theodre et al., all of them reported signiﬁcant reduction in
plantar fascia thickness.14,28,38
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esis of a signiﬁcant decrease in plantar fascia thickness associ-
ated with symptomatic improvement in the patient group with
PF subjective assessment by Mayo CSS was performed
3 months later and group B showed signiﬁcant improvement
in Mayo CSS score (t= 24.984, P< 0.001) with 52
(86.6%) patients showed good to excellent results. These ﬁnd-
ings were in common with Wang et al.,33 they compared the
effect of ESWT vs. conservative treatment for plantar fasciitis,
the patients experienced signiﬁcant improvement in pain and
function by Mayo CSS. Additionally, Wen et al. reported that
Mayo CSS score increased post ESWT with good to excellent
result rate 86.9 + 18.2.38 A recent Study in 2006 compared
ESWT versus a sham procedure in 172 patients. The research-
ers found a statistically signiﬁcant improvement of function
and reduction of pain of group treated by ESWT over the
sham treatment after 12 weeks and the patients experienced
no signiﬁcant complications or side effects.20 A meta-analysis
identiﬁed eight acceptable studies of sufﬁcient duration of fol-
low up (one year after treatment); the report concluded that
the therapeutic application of ESWT is clinically effective for
the treatment of chronic proximal plantar fasciitis.26,49
It was found that BMI of both groups (28.8 ± 2.61 and
29.523 ± 2.896) respectively, falls in the overweight category
and there was a signiﬁcant positive correlation between BMI
and PF thickness pre treatment in both groups. This is in accor-
dance with Ozdemir et al. and Heurta et al. they reported a
signiﬁcant positive correlation between BMI and Plantar fasci-
itis.9,40 This could be referred to possible association between
plantar fasciitis formation and overloading, as overweight lead
to chronic stretch and focal pressure on plantar fascia lead to
PF.11
In the current study, the reduction of plantar fascia thick-
ness measured by U/S in both groups was statistically signiﬁ-
cant post treatment after 12 weeks. Although, the reduction
in the thickness was more in ESWT group than local injection
group, yet did not reach signiﬁcant value. Those results are
similar to those reported by Porter and Shaadbolt, found that
ESWT and CS injection proved signiﬁcant improvements in vi-
sual analogue scale and heel tenderness index scores, but be-
tween the two groups there was no signiﬁcant difference in
the VAS score change 3 months after treatment.18
Recently, Yucel et al.44 compared high-Dose ESWT and
intralesional CS injection in the treatment of PF. In their
study, they reported that the two treated groups showed signif-
icant improvements in visual analogue scale and heel tender-
ness index scores, but between the two groups there was no
signiﬁcant difference 3 months after treatment. Pribut, found
out that CS injection and ESWT are successful treatment
modalities for plantar fasciitis. However, local corticosteroid
injection treatment is cost effective compared with ESWT,
and CS injection may be the ﬁrst treatment choice according
to their results.17
Others studies for PF have had conﬂicting results; undoubt-
edly that many issues surrounding ESWT like shockwave
dosage, high versus low-energy ESWT, and the n umber of ses-
sions required for a therapeutic effect.34 while, It was previ-
ously ascertained that efﬁcacy of ESWT may be highly
dependent upon machine types and treatment protocols.28,36
However, much more work needs to be done in order to deter-
mine the best protocols and patient selection for the use of
shock wave therapy.275. Conclusion
Both local steroid injection and ESWT are proved effective in
treatment of plantar fasciitis. Both groups showed signiﬁcant
clinical and ultrasound documented improvement of their dis-
ease after therapy with a slightly superior results of the ESWT
group, yet we do recommend local steroid injection as our pre-
ferred method of treatment being more cost effective and has
more reproducible results regardless of the machine or the
operator. However, ESWT should be considered prior to any
surgical treatment for recalcitrant PF.Acknowledgement
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